In summary, we show that SETD1A loss renders ATM-deficient and BRCA1-mutated breast, lung, and ovarian cancer cells resistant to PARPi by restoring HR, and that this is partly driven by defective EME1 transcription. This evidence concerns the gene BRCA1 and ovarian cancer.